Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey
Open Access
- 9 May 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 23 (8) , 827-832
Abstract
Few data are available on subjective disease control and perception of adverse events (AEs) during switching from original anti-TNF agents to biosimilars.Hungarian patients with inflammatory bowel ...Keywords
This publication has 31 references indexed in Scilit:
- Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic ReviewCurrent Medicinal Chemistry, 2019
- Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature reviewCurrent Medical Research and Opinion, 2016
- The nocebo effect of drugsPharmacology Research & Perspectives, 2016
- Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide CohortJournal of Crohn's and Colitis, 2015
- Developing Oncology Biosimilars: An Essential Approach for the FutureSeminars in Oncology, 2013
- Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaireGut, 2013
- The burden of inflammatory bowel disease in EuropeJournal of Crohn's and Colitis, 2013
- Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006Inflammatory Bowel Diseases, 2011
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Tumour-necrosis-factor antibody treatment in Crohn's diseaseThe Lancet, 1993